Trump ad­min­is­tra­tion opens the door to low­er drug prices as Medicare Ad­van­tage plans are pushed to step ther­a­py ap­proach

The Trump ad­min­is­tra­tion has tak­en an­oth­er step to­wards low­er­ing drug costs for con­sumers, this time aim­ing at the mil­lions of mem­bers in Medicare Ad­van­tage plans.

Un­der new rules an­nounced late Tues­day, the ad­min­is­tra­tion is giv­ing these plans the right to set up what’s called step ther­a­py plans for physi­cian-ad­min­is­tered and oth­er Part B drugs. These plans, com­mon­ly used among pri­vate in­sur­ers, man­date that mem­bers use the least ex­pen­sive drugs avail­able for their con­di­tions be­fore mov­ing on to prici­er ther­a­pies if need­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER